ARDS has been identified as the leading cause of COVID-19-related fatalities; in preclinical studies, Orbsen Therapeutics’ proprietary ORBCEL cellular therapy demonstrated the ability to mitigate the effects of ARDS by improving lung oxygenation, lessening inflammation, reducing edema and decreasing bacterial infection LOS ANGELES, April 15, 2020 (GLOBE NEWSWIRE) — via NetworkWire – Addressing the finding that most fatalities from COVID-19 are caused by the nonreversible development of acute respiratory distress syndrome (ARDS), Multiverse Investment Fund I, LP, a private…
Finalists in Global Competition to Present to Members of Investment and Venture Capitalists Communities Los Angeles, CA: (PRWEB) June 15, 2017 — Vault Pharma, an immunology-focused biotechnology company developing precision therapies for cancer, Women’s health, and infectious diseases, has been selected as a finalist and will present before an international panel of judges and investors on June 21, 2017, in San Diego at Start-Up Stadium at the BIO International Convention, the world’s largest biotechnology event….
Two new board members have histories of building successful pharma companies. Los Angeles, CA (PRWEB) May 08, 2017 — Vault Pharma, an immunology-focused biotechnology company developing precision therapies for cancer and infectious diseases, named Michael J. Kamdar, Chief Executive Officer and Director at Molecular Assemblies Inc., and Todd N. Smith, Chief Executive Officer at Novum Pharma, to the company’s Board of Directors. “Mike and Todd add depth, experience and leadership to an already distinguished group…
Experienced Biotech Leader To Guide Company As Therapies Enter Clinical Trials (PRWEB) April 27, 2017 — Los Angeles – Vault Pharma, an immunology-focused biotechnology company developing precision therapies for cancer and infectious diseases, named Oliver Foellmer as President and Chief Executive Officer. Vault Pharma is developing a unique therapeutics platform using the body’s own naturally occurring vault protein particles found abundantly in human cells to activate the immune system against cancer cells, bacteria and viruses….
Los Angeles, California – June 22, 2015. Vault Pharma (VPI) (www.vaulpharma.com), a biotechnology company developing immune therapies for cancer and infectious diseases, announced the addition of two high profile immune oncology experts to its Scientific Advisory Board. James Mulé Ph.D. and Antoni Ribas M.D. Ph.D. will join scientific founder Leonard Rome Ph.D. and Paul Wender Ph.D. in advising the company on research and development efforts. “This is a tremendous step for VPI,” said Michael…
Los Angeles, California – February 6, 2015. Vault Pharma announced that it has been granted a U.S. patent titled Vault Complexes for Cytokine Delivery. This patent supports Vault Pharma’s ImmunOncologyTM portfolio, a group of new medicines activating specific responses of the immune system to destroy cancer. Vault Pharma’s lead cancer drug, VPI-101, is a cytokine-based immune stimulant that is delivered by a novel human protein nanoparticle, called a vault. VPI-101 is on schedule to…
Los Angeles, California – January 19, 2015. Vault Pharma announced that its clinical manufacturing collaboration with Protein Sciences Corporation has been initiated to produce its lead immunotherapeutic against lung cancer. The collaboration is for the production of Vault Pharma’s lead cancer drug, VPI-101. VPI-101 is a cytokine-based immune stimulant that is delivered by a novel human protein nanoparticle, called a vault. Discovered at UCLA, vaults are being commercialized for a number of therapeutic indications…